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Glucocorticoids can activate the α-ENaC gene promoter independently
of SGK1
Niall MCTAVISH, Jennet GETTY, Ann BURCHELL and Stuart M. WILSON1
Centre for Cardiovascular and Pulmonary Research, Division of Medical Sciences, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, U.K.
The role of SGK1 (serum- and glucocorticoid-induced protein
kinase 1) in the glucocorticoid induction of α-ENaC (epithelial
Na
+ channel α subunit) gene transcription was explored by moni-
toring the transcriptional activity of a luciferase-linked, α-ENaC
reporter gene construct (pGL3-KR1) expressed in H441 airway
epithelial cells. Dexamethasone evoked a concentration-depend-
ent (EC50∼4 μM) increase in transcriptional activity dependent
upon a glucocorticoid response element in the α-ENaC sequence.
Although dexamethasone also activated endogenous SGK1,
artiﬁcially increasing cellular SGK1 activity by expressing a
constitutively active SGK1 mutant (SGK1-S422D) in hormone-
deprived cells did not activate pGL3-KR1. Moreover, expression
of catalytically inactive SGK1 (SGK1-K127A) suppressed the
activation of endogenous SGK1 without affecting the transcrip-
tionalresponsetodexamethasone.IncreasingcellularPI3K(phos-
phoinositide 3-kinase) activity by expressing a membrane-
anchoredformofthecatalyticPI3K-P110α subunit[CD2(cluster
of differentiation 2)-P110α] also activated endogenous SGK1
withoutaffectingpGL3-KR1activity.Acatalyticallyinactiveform
of CD2-P110α (R1130P), on the other hand, prevented the
dexamethasone-induced activation of SGK1, but did not inhibit
the activation of pGL3-KR1. However, expression of SGK1-
S422D or CD2-P110α enhanced the transcriptional responses
to maximally effective concentrations of dexamethasone and
this effect occurred with no change in EC50. Dexamethasone-
induced(0.3–300 nM)activationofpGL3-KR1wasunaffectedby
inhibitors of PI3K (PI-103 and wortmanin) and by rapamycin, a
selective inhibitor of the TORC1 (target of rapamycin complex 1)
signalling complex. Dexamethasone-induced activation of the
α-ENaC gene promoter can thus occur independently of SGK1/
PI3K, although this pathway does provide a mechanism that
allows this transcriptional response to dexamethasone to be
enhanced.
Key words: airway epithelium, epithelial Na
+ channel (ENaC)
dexamethasone,phosphoinositide3-kinase(PI3K),reportergene,
serum- and glucocorticoid-induced protein kinase 1 (SGK1).
INTRODUCTION
The integrated functioning of the respiratory tract is dependent
upon the controlled absorption of Na
+ from the liquid ﬁlm that
covers the lung/airway epithelia, and glucocorticoid hormones
are important to the induction and maintenance of this Na
+-
absorbingphenotype[1–3].EpithelialNa
+ absorptionoccursviaa
‘leak–pump’ mechanism [4], in which the overall rate of Na
+
absorption is restricted by the rate of apical Na
+ entry, and this
rate-limiting inﬂux of Na
+ occurs via ENaCs (epithelial Na
+
channels), transport proteins composed of three subunits (α-, β-
and γ-ENaC) encoded by separate genes [5,6]. In unstimulated
cells, apical Na
+ permeability appears to be restricted by the
continual internalization of ENaC, and this process is mediated
by Nedd-4/2 (neural precursor cell expressed, developmentally
down-regulatedprotein4-2),anubiquitinligasethatbindstoWW
domains (protein–protein interaction modules characterized by
two conserved proline residues spaced 20–22 amino acids apart)
on β-a n dγ-ENaC, thus targeting the ENaC channel complex for
ubiquitination, internalization and degradation [7,8]. Glucocor-
ticoids induce expression of SGK1 (serum- and glucocorticoid-
induced protein kinase 1) [9,10], a regulatory kinase that
phosphorylates Nedd-4/2, thus blocking this protein’s interaction
with ENaC. Activating SGK1 therefore allows ENaC to remain
in the apical membrane, leading to a rise in Na
+ permeability and
a stimulation of Na
+ absorption [7,8]. However, glucocorticoid
hormones also control α-ENaC transcription by activating a
GRE (glucocorticoid receptor response element) in this gene’s
promoter region, and this provides another mechanism that
allows these hormones to contribute to the control of Na
+
absorption [11–13]. It is therefore interesting that studies of
renal epithelia have indicated that SGK1 may also play a role
in the control of α-ENaC transcription [14]. Since this may
have implications for our understanding of the ways in which
glucocorticoids control pulmonary Na
+ transport, the present
study explores the relationship between cellular SGK1 activity
and α-ENaC transcription in glucocorticoid-stimulated human
airway epithelial cells.
EXPERIMENTAL
Cell culture and molecular biology
Experiments were undertaken using a human distal airway
epithelial cell line (H441) that expressed an endogenous Na
+
conductance essentially identical with that associated with α-, β-
and γ-ENaC co-expression [6]. Since the activity of this Na
+
conductanceisstrictlydependentuponglucocorticoidstimulation
[15], these cells provide a valuable experimental system with
which to explore the factors that allow these hormones to control
Na
+ transport [15]. Standard techniques were used to maintain
thesecellsinserialculture[16],andexperimentswereundertaken
Abbreviations used: Af9, ALL-1 fused gene from chromosome 9; CD2, cluster of differentiation 2; df, degrees of freedom; Dot1a, disruptor of telomeric
silencing alternative splice variant a; ENaC, epithelial Na+ channel; GRE, glucocorticoid response element; Nedd-4/2, neural precursor cell expressed,
developmentally down-regulated protein 4-2; NDRG1, N-myc downstream regulated gene 1; PIM1 and 3, provirus integration site for Moloney murine
leukaemia 1 and 3; SGK1, serum- and glucococorticoid-induced protein kinase; PI3K, phosphoinositide 3-kinase; TORC, target of rapamycin complex.
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using cells removed from culture ﬂasks using trypsin/EDTA and
plated on to 24-well (reporter gene assays, 7.5×10
4 cells/well)
or six-well (Western analysis, 3×10
5 cells/well) plates. Cellular
SGK1 activity was artiﬁcially increased by transfecting cells
with a cDNA construct encoding a glutathione transferase-fusion
protein incorporating a truncated form of SGK1 which lacked
60 N-terminal amino acid residues and which had been further
modiﬁed by mutating SGK1-Ser
422 to aspartate (SGK1-S422D).
The N-terminal truncation increases the expression of this protein
by preventing its degradation, and the S422D mutation allows
SGK1 to be activated by PDK1 (3-phosphoinositide-dependent
protein kinase 1) [10,18]. Taken together, these mutations
confer a constitutively active phenotype [18]. Non-speciﬁc
effects of the transfection and/or heterologous protein expression
were controlled for using an analogous construct encoding a
catalytically inactive form of SGK1, SGK1-K127A [18]. The
role of PI3K (phosphoinositide 3-kinase) was explored by
expressing a chimaeric protein consisting of the catalytic P110α
domain of PI3K (PI3K-P110α) attached to the extracellular and
transmembrane domains of the rat CD2 surface antigen. The CD2
domain effectively anchors the PI3K-P110α subunit to the
inner surface of the membrane. PI3K activity was enhanced
using a construct encodingwild-type PI3K-P110α (CD2-P110α),
and the corresponding control construct (CD2-P110α-R1130P)
incorporatedacatalyticallyinactivemutant.Thissystemhasbeen
detailed previously in [19].
Transcriptional activity of the α-ENaC promoter
Activation of the promoter region of the α-ENaC gene was
assayed by transfecting cells on 24-well plates using Lipofect-
amine
TM 2000 with a luciferase-linked reporter gene construct
(pGL3-KR1) incorporating 2.2 kb of the α-ENaC gene sequence
corresponding to nucleotides −1388 to +830 relative to the start
site for the α-ENaC-1 transcript. This gene sequence includes
exon1A,intron1,thestartsitefortheα-ENaC-2transcriptandthe
GREatposition−141to−155thatisknowntoregulatetranscrip-
tion [12,13]. In all experiments the transfected cells were initially
maintained (24 h) in a fully deﬁned culture medium prepared
using dialysed serum devoid of glucocorticoids [16]. Glucocorti-
coid-deprived cells were exposed to this medium throughout the
entire experimental period, whereas dexamethasone-stimulated
cells were exposed to this synthetic glucocorticoid as detailed
below. Experiments were terminated by lysing the cells so that
luciferase formation could be quantiﬁed (Wallac 1420 Victor
plate reading luminometer/Promega luciferase assay system) and
normalized to the amount of cellular protein in each well, which
was determined using Bradford reagent. Some experiments were
undertaken using a reporter construct that had been modiﬁed by
deleting(StratageneQuikChangeIIsite-directedmutagenesiskit)
ﬁve nucleotides (position −150 to −155) in order to disrupt the
GRE that has previously been documented in the α-ENaC gene
promoter [12,13].
Experimental design and data analysis
All pGL3-KR1 activities were expressed as fold increases over
the basal activity measured in cells expressing the empty pGL3
vector (pGL3-basic). Hormone-sensitive pGL3-KR1 activity was
quantiﬁed by subtracting the activity measured in glucocorticoid-
deprived cells from the activity measured in dexamethasone-
stimulated cells, and all such data are shown as percentages of the
activity measured in cells exposed to a maximally effective con-
centration of dexamethasone. To allow comparison between
different data sets, the response to this standard stimulus was
quantiﬁed in every experiment. Plots showing the relationship
between hormone-sensitive pGL3-KR1 activity and dexamethas-
one concentration were constructed and sigmoid curves ﬁtted
to the pooled data by least-squares regression. Since the back-
ground activity was deﬁned experimentally, the algorithm used
to ﬁt this curve (Graﬁt 5; Erithacus Software) estimated (i) the
concentration of dexamethasone needed for half-maximal activ-
ation (EC50); (ii) the maximal response (Rmax), and (iii) the Hill
Coefﬁcient. This software package also provided an estimate
of the standard error associated with each parameter and the
statistical signiﬁcance of any apparent differences between data
setscouldthusbetestedbycalculatingavalueofStudent’st using
the equation:
t = (Param1 − Param2)/

(SE
2
1 − SE
2
2)
where Param1 and Param2 are the respective parameters
measured under different conditions (i.e. EC50 or Rmax)a n d
SE1 and SE2 represent their respective standard errors. Each
curve was deﬁned by six or seven different dexamethasone
concentrations and was therefore ﬁtted with three or
four df (degrees of freedom). This, in turn, implies that
the values of t derived from this equation are asso-
ciated with six or eight df, and these were therefore used to
estimate the two-tailed probabilities (P) that the two parameters
are derived from the same statistical populations. Values of
P<0.05 were considered to be signiﬁcant. Values of n denote the
number of times a protocol was repeated using cells at different
passage number and all results are means+ −S.E.M.
Assay of SGK1 activity
ChangesincellularSGK1activityweremonitoredusingphospho-
speciﬁcantibodiestomonitorbyWesternanalysisthephosphoryl-
ation of residues (Thr
346/356/366) within an endogenous protein
(NDRG1;N-myc-downstreamgene1)thatarephosphorylatedby
SGK1 but not by other kinases, including the closely related PKB
(protein kinase B) [20–22]. Although it is now clear that changes
to the phosphorylation status of these residues can provide a read-
out of cellular SGK1 activity (see e.g. [22,23]), our experience is
that there can be variations in the magnitudes of the responses
measured in different experiments. To ensure that this effect
did not confound analysis of the present data, all experiments
were undertaken using strictly paired experimental designs in
which the control and experimental cells were age-matched and
at identical passage. Great care was taken to handle all protein
samples identically and, in all experiments, proteins extracted
from control and experimental cells were processed in parallel
using identical reagents and then fractionated on the same gels
so that they could be analysed in exactly the same way. A full
account of this method [22], and a detailed review of its rationale
[20,21], are published elsewhere.
RESULTS
Glucocorticoid-induced activation of the α-ENaC gene promoter
When expressed in glucocorticoid-deprived cells, the activity of
the pGL3-KR1 reporter gene was 7.3+ −1.0-fold greater (n=49,
P<0.0001, Student’s paired t test) than the activity measured
in cells expressing the empty pGL3 vector. Dexamethasone
(0.1 μM) consistently evoked luciferase synthesis in pGL3-KR1-
expressing cells and, since this response was not seen in cells ex-
pressing the empty vector (results not shown), this ﬁnding
conﬁrms that this synthetic glucocorticoid normally activates the
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Figure 1 Dexamethasone-induced activation of pGL3-KR1
(A)Timecoursesshowingtheeffectsofdexamethasone(0.1 μM)uponluciferaseaccumulation
in cells expressing either wild-type (wt) α-ENaC reporter construct (pGL3-KR1, n=10) or
the construct incorporating the mutant α-ENaC sequence lacking the functional GRE (GRE-del,
n=5). (B) Concentration–effect curves showing the effects of dexamethasone (18h) upon
the activity of pGL3-KR1 activity both under control conditions (n=8) and in the presence of
2.5 μM mifepristone (n=8).
α-ENaC gene promoter. This response became apparent after
∼6 h, reached a plateau at ∼18 h (Figure 1A) and was abolished
by disrupting the GRE that has previously been shown to regulate
the activity of this gene promoter (Figure 1A). Experiments in
which luciferase formation was quantiﬁed in cells exposed to
0.3–300 nM dexamethasone for 18 h showed that this response
was concentration-dependent, and the EC50 was estimated to
be 3.7+ −0.4 nM (Figure 1B), a value similar to that reported
in a previous study [25]. Concentrations of dexamethasone
>30 nM usually evoked maximal responses, although, in some
experiments, high concentrations of dexamethasone evoked sub-
maximal responses, indicating that this response can be subject to
desensitization.Theactivationofthisreportergenewasabolished
bymifepristone,aglucocorticoidreceptorantagonist(Figure1B),
and it is therefore clear that this response reﬂects glucocorticoid
receptor-mediated activation of the GRE that has been previously
described in the promoter region of the α-ENaC gene [11–13].
SGK1-induced phosphorylation NDRG1-Thr346/356/366
Western blot analyses of protein extracted from unstimulated and
dexamethasone-treated(0.1 μM,18 h)cellsexpressingtheempty
pGL3 vector showed that this synthetic glucocorticoid increased
the abundance of the Thr
346/356/366-phosphorylated NDRG1 with
no effect upon the overall expression of this protein (Figure 2).
This response was essentially identical with that reported in
previous studies of untransfected cells [22] and it is therefore
clear that exposure to transfection reagents does not alter
this response. Parallel studies of glucocorticoid-deprived cells
expressingSGK1-S422DrevealedaclearstimulationofNDRG1-
Thr
346/356/366 phosphorylation and this response, in common with
the response to dexamethasone, occurred with no change in the
overall NDRG1 abundance (Figure 2). Dexamethasone stimul-
ation had no further effect upon the phosphorylation of NDRG1
Figure 2 Activation of SGK1
(A) Control (i.e. cells transfected with empty vector; Cont.) cells and cells transiently
expressing either SGK1-S422D or SGK1-K127A were maintained in hormone-free medium
or stimulated with 0.1 μM dexamethasone (Dex) for 18h. All cells were then lysed and 15μg
aliquots of cellular protein were fractionated by SDS/PAGE, blotted on to Hibond membranes
which were then probed using antibodies against the Thr346/356/366 phosphorylated form of
NDRG1 (upper panel) or total NDRG1 (lower panel). (B) Densitometric analysis showing the
pooled (means+ −S.E.M.) from six independent experiments. Unstim., unstimulated; Dex.,
dexamethasone.
inSGK1-S422D-expressingcells(Figure2).Transientexpression
of SGK1-K127A had no effect upon the phosphorylation
status of NDRG1-Thr
346/356/366 in dexamethasone-deprived cells,
but this catalytically-inactive form of SGK1 suppressed
the dexamethasone-induced phosphorylation of Thr
346/356/366 in
NDRG1 (Figure 2). Since NDRG1-Thr
346/356/366 residues are
phosphorylated by SGK1 [20], these results (see also [22]) show
that this catalytically inactive form of SGK1 suppresses the
hormonal activation of this kinase.
SGK1-induced activation of pGL3-KR1
To explore the role of SGK1 in the transcriptional response to
dexamethasone, we assayed the transcriptional activity of pGL3-
KR1 in control cells (i.e. cells expressing the empty vector)
and in cells transiently expressing SGK1-S422D and SGK1-
K127A. Analysis of data derived from glucocorticoid-deprived
cells showed that the basal activity of pGL3-KR1 was ∼9-fold
greater than the activity associated with the empty pGL3
vector (Figure 3A). SGK1-S422A-expressing cells displayed an
essentially identical level of activity (Figure 3A) and, although
the basal activity measured in cells expressing SGK1-K127A
appeared slightly lower than control (Figure 3A), this effect
was not statistically signiﬁcant (one-way ANOVA). The data
in Figure 3(B) show that dexamethasone normally caused
concentration-dependent activation of pGL3-KR1 in SGK1-
K127A-expressing cells, and the EC50 measured under these
conditions (4.7+ −0.5 nM), did not differ signiﬁcantly from that
measured in age-matched control cells at identical passage
(Figure 3B). The maximal response to dexamethasone (Rmax)w a s
also essentially identical (93.6+ −2.8%) with the control, and so
the expression of this inactive SGK1 mutant has no discernible
effect upon the transcriptional response to dexamethasone.
Analysis of the data derived from SGK1-S422D-expressing cells
showed that this constitutively active mutant had no effect
upon the responses to low concentrations of dexamethasone,
but enhanced the responses to the highest concentrations
t e s t e d( F i g u r e3 B ) .T h ev a l u eo fRmax measured in these cells
(188+ −13%) was therefore greater (t=7.28, df=8, P<0.0001)
than the value measured in SGK1-K127A-expressing cells, and
this effect occurred with no change in EC50 (5.9+ −1.6 nM).
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Figure 3 Role of SGK1 in α-ENaC transcription
(A) Luciferase formation (18h, n=9) was quantiﬁed in hormone-deprivedcells co-expressing
the α-ENaC reporter gene in conjunction with SGK1-S422D or SGK1-K127A; control (Cont.)
cells expressed this reporter gene construct together with the empty pEGB vector. (B) Dexa-
methasone-induced (18h) activation of pGL3-KR1 in control cells (i.e. cells expressing
pGL3-KR1 and pEGB) and in cells co-expressing either SGK1-S442D or SGK1-K127A (n=8).
The continuous curves were ﬁtted to the experimental data by least-squares regression. All
results are normalized to the luciferase formation measured in cells expressing the empty pGL3
vector and are shown as means+ −S.E.M.
PI3K-induced NDRG1-Thr346/356/366 phosphorylation
Figure 4 shows the results of experiments that quantiﬁed
NDRG1-Thr
346/356/366 phosphorylation in glucocorticoid-deprived
and dexamethasone-stimulated cells transiently expressing the
chimaeric proteins incorporating the catalytic PI3K-P110α
subunit. Results derived from control cells conﬁrmed (in the
present study and [22]) that dexamethasone (0.1 μM, 18 h)
evokes the phosphorylation of these residues with no effect upon
the overall NDRG1 abundance, conﬁrming that glucocorticoids
normally increase SGK1 activity (see [20,22]). Transient
expression of CD2-P110α also evoked NDRG1-Thr
346/356/366
phosphorylation with no effect upon the overall expression,
indicatingthatartiﬁciallyincreasingcellularPI3Kactivitymimics
theeffectsofglucocorticoidstimulationbyactivatingendogenous
SGK1 (Figure 4). Dexamethasone stimulation had no further
effect upon the phosphorylation of NDRG1-Thr
346/356/366 in CD2-
P110α-expressing cells (Figure 4). Expression of CD2-P110α-
R1130, which incorporates a catalytically inactive form of the
PI3K-P110α subunit, had no effect upon NDRG1 Thr
346/356/366
phosphorylation in glucocorticoid-deprived cells, but prevented
theincreasedphosphorylationoftheseresiduesthatwasnormally
seen in glucocorticoid-stimulated cells (Figure 4). Since PI3K is
knowntocontrolthephosphorylation/activationofSGK1[18,26],
the results from the present study indicate that the transient
expression of CD2-P110α-R1130 exerts a dominant-negative
Figure 4 Effects of increasing cellular PI3K activity
(A) Control cells (i.e. cells transfected with empty vector; Cont.) and cells transiently
expressing either CD2-P110α orCD2-P110α-R1130Pwereeither maintained in hormone-free
medium or stimulated with 0.1μM dexamethasone (Dex) for 18 h. All cells were then
lysed and 15μg aliquots of cellular protein fractionated so that the cellular abundance of
Thr346/356/366-phosphorylated NDRG1 (upper panel) and total NDRG1 (lower panel) could be
assayed by Western analysis. (B) Densitometric analysis showing the pooled means+ −S.E.M.
from ten independent experiments. Unstim., unstimulated; Dex., dexamethasone; wt, wild-type.
effect by suppressing the glucocorticoid-induced activation of
SGK1 (Figure 4).
PI3K-induced activation of pGL3-KR1
Experiments in which the activity of the α-ENaC reporter gene
construct was monitored in hormone-deprived cells conﬁrmed
(in the present study and [25]) that the basal activity of this
construct is ∼10-fold greater than that associated with the
empty vector (Figure 5A). Initial examination of the results of
experiments in which transcriptional activity was quantiﬁed in
cells expressing CD2-P110α or CD2-P110α-R1130P suggested
that the expression of these chimaeric proteins might inhibit
pGL3-KR1 (Figure 5A). However, these apparent effects did not
reach statistical signiﬁcance (one-way ANOVA), and so neither
construct has any direct effect upon the transcriptional activity
of the promoter region of the α-ENaC gene. These experiments
also explored the effects of dexamethasone (18 h, 1–300 nM)
upon pGL3-KR1 activity in cells expressing these chimaeric
proteins. As anticipated, studies of control cells conﬁrmed
that this hormone normally induces concentration-dependent
activation of the α-ENaC gene promoter (see above). Although
this response was also seen in CD2-P110α-R1130P-expressing
cells,analysisoftheseresultsindicatedthatthemaximalresponse
to dexamethasone (Rmax =1.84+ −0.06, Figure 5B) was greater
than control (P<0.05). However, the most important result to
emerge from these studies was that the value of Rmax measured
in cells expressing the catalytically active CD2-P110α protein
was greater (t=8.11, df=4, P<0.0001) than the maximal
response measured in cells expressing CD2-P110α-R1130P. It
is therefore clear that increasing cellular PI3K activity enhances
the dexamethasone-induced activation of the α-ENaC reporter
gene construct.
Effects of cell stress
As well as being induced by glucocorticoid hormones, data from
several different cell types show that SGK1 activity/expression
is enhanced by stressful stimuli [9,27–31], and we therefore
explored the effects of such stimuli on SGK1 activity in H441
cells. Initial studies (n=5) showed that 2 h exposure to a
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Figure 5 Role of PI3K in α-ENaC transcription
(A)TheexperimentalprotocolshowninFigure3wasusedtomonitorthetranscriptionalactivity
of pGL3-KR1 in hormone-deprived control (Cont.) cells and in expressing either CD2-P110α
(wild-type, wt) or CD2-P110α-R1130P. (B) Dexamethasone-induced (18h) activation of
pGL3-KR1incontrolcellsandincellsexpressingeitherCD2-P110α-wtorCD2-P110α-R1130P
(n=9).Thecontinuouscurveswereﬁttedtotheexperimentaldatabyleast-squaresregression.
AlldataarenormalizedtotheluciferaseformationmeasuredincellsexpressingtheemptypGL3
vector and are shown as means+ −S.E.M.
hyperosmotic external solution (prepared by adding 300 mM
sorbitol to the standard culture medium) had no effect upon
NDRG1 phosphorylation assayed after a 12 h recovery period.
Similarly exposing cells (n=4) to increased ambient temperature
(42◦C ,1h )o rH 2O2 (0.5 mM, 1–2 h) also had no effect upon the
phosphorylation of these residues. However, exposing cells to a
brief <1 s pulse of UV light (50 J·m
2; Spectronic Corporation
Spectrolinker) consistently increased the phosphorylation of
NDRG1-Thr
346/356/366 assayed after a 2 h recovery period, and
this stimulus therefore provides a way of activating endogenous
SGK1 independently of stimulating hormones (Figures 6A and
6B). However, subsequent experiments showed that irradiating
the cells with UV light in this way had no direct effect upon the
transcriptional activity of the α-ENaC gene promoter and also
failed to modify the transcriptional response to dexamethasone
(Figure 6C).
Effects of PI3K inhibitors
Figure 7 shows the results of experiments that used a strictly
paired protocol to study the effects of PI3K inhibitors upon the
dexamethasone-induced (0.3–100 nM) activation of pGL3-KR1.
Although LY294002 (50 μM) had no effect upon the EC50 for
dexamethasone (control: 3.4+ −0.4 nM; LY294002-treated: 3.2+ −
0.5 nM), this substance caused ∼30% inhibition (t=13.41,
df=6, P<0.0001) of the maximal response to this hormone
(Figure 7A). Wortmannin, on the other hand, had no effect upon
EC50 (control: 4.1+ −0.3 nM; wortmannin-treated: 6.4+ −3.8 nM)
Figure 6 Effects of UV irradiation upon the phosphorylation of NDRG1-
Thr346/356/366 and the activity of the α-ENaC reporter gene construct
(A) Western blots showing the effects of dexamethasone (Dex., 0.1μM, 6h) and UV
irradiationuponthecellularabundanceofThr346/356/366-phosphorylatedandtotalNDRG1.Cont.,
control. (B) Densitometric analysis showing the pooled means+ −S.E.M. from ﬁve independent
experiments; asterisks denote statistically signiﬁcant differences from the control (Cont.) value
(Student’s paired t test). Dex., dexamethasone (C) Results of a series of experiments (n=5)
undertaken using a strictly paired experimental design that explored the effects of UV irrdiation
upon the dexamethasone (Dex.) induced (0.1 μM, 6 h) activation of the α-ENaC reporter gene
construct. Asterisks denote statistically signiﬁcant effects of dexamethasone (Student’s paired
t test). Unstim., unstimulated.
or the maximal response (Figure 7B). Although PI-103 appeared
to cause a slight leftward shift in the concentration–response
curve, this effect was not statistically signiﬁcant and so this
compound did not alter the EC50 (control: 3.7+ −0.09 nM; PI-
103-treated: 2.1+ −0.1 nM). PI-103 also had no effect upon the
magnitude of the maximal response (Figure 7C). Although
LY294002, wortmannin and PI-103 are often used as selective
inhibitors of PI3K, these compounds also inhibit TORC1, a
signalling complex dependent upon mTOR (mammalian target
of rapamycin) that controls many aspects of cellular physiology.
We therefore also explored the effects rapamycin, an exquisitely
selective inhibitor of TORC1 [32]. Rapamycin had no effect upon
the EC50 for dexamethasone (control: 3.2+ −0.3 nM; rapamycin-
treated: 3.2+ −0.5 nM), but enhancedthe maximal response to this
hormone (t=7.13, df=6, P=0.0004) by ∼75% (Figure 7D).
Analysis of protein extracted from glucocorticoid-deprived
cellsthathadbeenmaintainedundercontrolconditionsorexposed
to wortmannin/PI-103 showed that both substances reduced
(∼70%) the abundance of Thr
346/356/366-phosphorylated NDRG1,
with no effect upon the overall levels of NDRG1. As anticipated,
dexamethasone(0.1 μM)normallyincreasedthephosphorylation
of NDRG1-Thr
346/356/366 (Figure 8) and, although there was some
evidence of a residual response in the wortmannin/PI-103-treated
cells, this effect did not reach statistical signiﬁcance (Figure 8).
These experiments also explored the effects of LY294002 and,
as anticipated by our previous work [22], this compound caused
essentially complete dephosphorylation of NDRG1 and totally
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Figure 7 Dexamethasone-induced activation of the α-ENaC gene promoter
in cells treated with PI3K inhibitors or rapamycin
All experiments were undertaken using a strictly paired protocol in which
dexamethasone-induced (0.3–100nM, 18h) activation of pGL3-KR1 was monitored under
control conditions and in the presence of either 50μM LY294002 (A, n=13); 0.1 μM
wortmannin (B, n=8); 0.5μM PI-103 (C, n=8), or 100nM rapamycin (D, n=12). All
results were normalized to the control response evoked by a maximally effective concentration
of dexamethasone. This usually occurred in response to 100μM, but in some experiments this
highconcentrationofhormoneevokedasubmaximalresponse(asshowninB,CandD)andin
these experiments results were normalized to the response evoked by 30nM dexamethasone.
Results are shown as means+ −S.E.M. and sigmoid curves were ﬁtted to the pooled data by
least-squares regression.
Figure 8 Effects of PI3K inhibitors on the phosphorylation of NDRG1-
Thr346/356/366
(A) Western blots showing the effects of wortmannin (Wort.) (0.1 μM) and PI-103
(0.5 μM) upon the cellular abundance of Thr346/356/366-phosphorylated and total NDRG1 in
glucocorticoid-deprived and dexamethasone (Dex)-stimulated (0.1μM) cells. This protocol
was repeated ﬁve times using cells at different passage number. Cont. control (B) Results
from a directly analogous experiment showing effects of PI-103 (0.5 μM) and LY294002
(Ly; 50μM). This protocol was repeated ﬁve times. Dex, dexamethasone; Cont.,
control. (C) Densitometric analysis showing the pooled means+ −S.E.M. from all
experiments. Unstim., unstimulated; Dex, dexamethasone; Cont., control; Wort., Wortmannin;
LY, LY294002.
Figure 9 Effects of rapamycin upon the phosphorylation of NDRG1-
Thr346/356/366
(A) Western blots showing the effects of rapamycin (0.1μM) on the cellular
abundance of Thr346/356/366-phosphorylated and total NDRG1 in glucocorticoid-deprived and
dexamethasone(Dex)-stimulated(0.1μM)cells.(B)Densitometricanalysisshowingthepooled
means+ −S.E.M. from ﬁve independent experiments. Rap., rapamycin.
abolished the response to dexamethasone. Further experiments
showed that rapamycin had no signiﬁcant effect upon the
phosphorylation status of these residues in either glucocorticoid-
deprived or dexamethasone-stimulated cells (Figure 9).
DISCUSSION
Dexamethasone-induced activation of the α-ENaC gene promoter
When expressed in glucocorticoid-deprived cells, the α-ENaC
reporter gene construct displayed a level of activity 5–10-fold
greater than that associated with the empty vector, and such low
basal activity has been documented in previous studies of the rat
and human α-ENaC promoters [11–13,25,33,34]. Dexamethas-
one consistently activated this reporter gene construct via a
mechanism dependent upon the GRE in the α-ENaC promoter
[11–13,25,33,34], and the fact that this response was abolished
by mifepristone, a glucocorticoid receptor antagonist, provides
further evidence for the involvement of these receptors. The
response to dexamethasone was concentration-dependent and the
half-maximal activation occurred at ∼4 nM (see also [25]). It
is therefore interesting that the oral administration of 1 mg of
dexamethasone increases the circulating concentration to ∼7n M
[35], whereas the intravenous administration of 5 mg leads to a
circulating concentration of 50–100 nM [36,37]. These clinically
relevant doses of dexamethasone therefore produce circulating
concentrations sufﬁcient to inﬂuence α-ENaC transcription and
this response may therefore contribute to the clinical effects
of this synthetic glucocorticoid.
Dexamethasone-induced phosphorylation of NDRG1-Thr346/356/366
Stimulation with dexamethasone also evoked phosphorylation of
NDRG1-Thr
346/356/366 and,sincetheseresiduesarephosphorylated
by SGK1 but not by other related kinases [20,21], this conﬁrms
that glucocorticoids activate SGK1 in these cells [10]. Our
recently published data [22] show that this response peaks after
∼2 h, and the fact that elevated SGK1 activity is still evident
after 18 h shows that the dexamethasone-induced activation of
the α-ENaC promoter coincides with increased SGK1 activity, an
observation consistent with the hypothesis that SGK1 is involved
in this transcriptional response [14,38].
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Effects of SGK1-S422D/SGK1-K127A
Expressing SGK1-S422D in glucocortcoid-deprived cells evoked
NDRG1-Thr
346/356/366 phosphorylation,anditisthereforeclearthat
the expression of this constitutively active protein provides a way
of increasing cellular SGK1 activity independently of stimulating
hormones (see also [22]). However, despite this clear ﬁnding,
expressing SGK1-S422D in glucocorticoid-deprived cells did not
alter the activity of the α-ENaC gene promoter and it is therefore
clear that a substantial increase in cellular SGK1 activity does
not provide a stimulus sufﬁcient to mimic the transcriptional
response to dexamethasone. This was surprising, since previous
studies of renal epithelia had indicated that SGK1 was important
to the control of α-ENaC gene transcription [38]. However, our
studies of dexamethasone-stimulated cells showed that SGK1-
S422D expression enhanced the response to concentrations of
dexamethasone >10 nM, and it is therefore clear that artiﬁcially
imposed increases in cellular SGK1 activity can enhance the
glucocorticoid-induced activation of the α-ENaC gene promoter
under certain experimental conditions.
Parallel studies of glucocorticoid-deprived cells expressing
SGK1-K127 showed that this mutant protein had no effect upon
NDRG1-Thr
346/356/366 phosphorylation,anditisthereforeclearthat
this catalytically inactive protein does not alter cellular SGK1 ac-
tivity. The activation of SGK1 seen in cells expressing SGK1-
S422D cannot, therefore, be attributed to increased activity of
endogenous SGK1 evoked by exposure to transfection reagents
and/or to the expression of heterologous protein. However,
the expression of SGK1-K127A did block the dexamethasone-
induced increase in NDRG1-Thr
346/356/366 phosphorylation, and
this catalytically inactive SGK1 mutant therefore seems to
display a dominant-negative phenotype. Transient expression
of this mutant protein therefore provides a way of disrupting
the hormonal activation of endogenous SGK1 but, despite this
clear ﬁnding, SGK1-K127A expression had no effect upon the
transcriptional response to dexamethasone. Although increases in
cellular SGK1 activity can augment the transcriptional response
to dexamethasone (see above), it therefore appears that the hor-
monal activation of endogenous SGK1 is not necessary for the
glucocorticoid-induced activation of the α-ENaC gene promoter.
Effects of CD2-P110α/CD2-P110α-R1130P
Three isoforms of SGK have been identiﬁed in mammalian cells
(SGK1–3) [27,39,40] and, although these share a high degree
of homology in the catalytic domain, they differ in N-terminal
structure. This variability is signiﬁcant, since this region of SGK1
inﬂuences protein stability and cellular localization [18,41–43].
Moreover, although SGK1 is the only isoform that is hormone-
sensitive, three splice variants of human SGK1 have been iden-
tiﬁed and these mRNA species encode proteins that also display
different N-terminal sequences [44]. These SGK1 variants may
therefore display different patterns of degradation and different
cellular locations, and this heterogeneity may explain, at least in
part, the diverse cellular functions of this kinase [10]. The fact
that 60 N-terminal residues were deleted from the constitutively
active form of SGK1 used in the present study implies that
this modiﬁed protein is not degraded as rapidly as full-length
SGK1 [18]. Moreover, this N-terminal deletion may also cause
theSGK1-S422Dproteintobelocatedtoaninappropriatecellular
compartment and so, although SGK1-S422D can clearly increase
cellular SGK1 activity, the transient expression of SGK1-S422
may not reproduce the effects of activating endogenous SGK1.
We therefore sought to identify a way of activating endogenous
SGK1 independently of stimulating hormones and, since the
catalytic activity of SGK1 is dependent upon PI3K-regulated
phosphorylation [9,18,23,26], we explored the effects of
transiently expressing a chimaeric protein encoding a membrane-
anchored form of the catalytic PI3K-P110α subunit [19]. Ex-
pressing this PI3K-activating protein in glucocorticoid-deprived
cells clearly evoked NDRG1-Thr
346/356/366 phosphorylation,
indicating increased activity of endogenous SGK1 [18,20,21,26].
Moreover, although a catalytically inactive control construct
(CD2-P110α-R1130P)didnotalterNDRG1phosphorylation,this
mutant protein did prevent the dexamethasone-induced increase
in NDRG1-Thr
346/356/366 phosphorylation, indicating that this
chimaeric protein displays a dominant–negative phenotype. It is
therefore interesting that electrophysiological studies undertaken
in this laboratory (M. Gallacher and S.M. Wilson, unpublished
work) have shown that the expression of CD2-P110α-R1130P
can partially suppress the glucocorticoid-induced Na
+ current in
these cells [15,16]. Transient expression of CD2-P110α-R1130P
thusseemstoprovideanotherwayofblockingtheglucocorticoid-
induced activation of SGK1.
Expressingthesechimaericproteinsinglucocorticoid-deprived
cellshadnoeffectuponthetranscriptionalactivityoftheα-ENaC
genepromoter,indicatingthatPI3K-mediatedactivationofSGK1
does not mimic the transcriptional response to dexamethasone.
Interestingly, although it has no catalytic activity, expressing
CD2-P110α-R1130P did enhance the transcriptional response to
dexamethasone. Although this unexpected response to a catalyt-
ically inactive protein cannot be mediated via PI3K or SGK1, it
is important to remember that this mutant protein would almost
certainly suppress the phosphorylation of PI3K targets other than
SGK1. It is therefore possible that a PI3K-dependent signalling
pathwaymaynormallyexertinhibitorycontroloverα-ENaCgene
transcription. However, the most important result to emerge from
these experiments was that expression of CD2-P110α augmented
the transcriptional response to dexamethasone to a level greater
thanthatmeasuredinCD2-P110α-R1130P-expressingcells.This
result accords well with the data derived from cells expressing
the modiﬁed forms of SGK1 and, taken together, these two
sets of independent experiments indicate that artiﬁcially imposed
increases in cellular SGK1 activity do not mimic the effects
of glucocorticoid stimulation but do enhance the transcriptional
responses to these hormones.
Pharmacological inhibition of PI3K
StudiesofcellsexpressingSGK1-K127AorCD2-P110α-R1130P
showed that glucocorticoids continue to activate the α-ENaC
promoter even if the activation of endogenous SGK1 is prevented
and so, although SGK1 augments the transcriptional response to
dexamethasone (see above), increased SGK1 activity does not
seem to be necessary for the hormonal activation of the α-ENaC
gene promoter. Since this contrasts with the situation in renal
epithelia where SGK1 is intimately involved in the control of
α-ENaC transcription [14,38], further experiments explored the
effects of pharmacological inhibitors of PI3K, since such com-
pounds characteristically cause a profound loss of SGK1 activity
(see e.g. [18,22,23]). Neither wortmanin nor PI-103 had any
effect upon the transcriptional response to dexamethasone, and
although LY294002 reduced the maximal response to this
hormone, this effect was relatively modest (∼30% inhibition)
and residual responses could clearly be seen in LY294002-
treated cells. Parallel analyses of extracted protein showed that
LY294002, PI-103 and wortmannin all reduced the phosphoryl-
ation of NDRG1-Thr
346/356/366, indicating these substances all
cause substantial inactivation of endogenous SGK1 [20,21].
However, although LY294002 appeared to cause a complete
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loss of activity (see also [22]), small amounts of Thr
346/356/366-
phosphorylated NDRG1 could still be detected in PI-103-treated
and wortmannin-treated cells, suggesting that these compounds
may not inactivate SGK1 fully. This discrepancy was surprising,
since all three compounds were used at concentrations thought
to cause complete inhibition of PI3K in intact cells [32], and
it may be relevant that, as well as inhibiting PI3K, LY294002 is
knowntoinactivateanumberofproteinkinasesincludingGSK3β
(glycogen synthase kinase 3β), PLK3 (polo-like kinase 3), CK2,
PIM1 (provirus integration site for Moloney murine leukaemia 1)
and PIM3, and it has been therefore suggested that the use of
LY294002 as a selective PI3K inhibitor should be discontinued
[32]. However, even if we accept that LY294002 is the only
tested compound that was able to cause complete inhibition of
PI3K, then the present data show that essentially complete loss of
endogenous SGK1 activity causes only a modest reduction of the
transcriptional response to dexamethasone.
Effects of rapamycin
Although often referred to as PI3K inhibitors, LY294002, wort-
mannin and PI-103 also inhibit the TORC1 signalling complex
[45,46], and this could be signiﬁcant for the present study, since it
has recently been proposed [47] that TORC1 catalyses the phos-
phorylation of SGK1-Ser
422, implying that TORC1 plays an
important role in the control of cellular SGK1 activity (see
[18,26]). We therefore also explored the effects of rapamycin,
since this compound has been shown to act as an exquisitely
selective inhibitor of TORC1 [32]. The ﬁrst such studies showed
that rapamycin augmented the glucocorticoid-induced activation
of the α-ENaC gene promoter, and it is therefore clear that
the inhibitory action of LY294002 described above cannot be
attributed to an effect on TORC1. Indeed, these data also suggest
that tonic activity of TORC1 may normally repress the activity
of this gene promoter. However, the most important result to
emerge from these studies was that rapamycin had no discerni-
ble effect upon NDRG1-Thr
346/356366 phosphorylation in gluco-
corticoid-deprived or dexamethasone-stimulated cells. Since
separate experiments in this laboratory have shown that 2–3 h
exposure to 0.1 μM rapamycin essentially abolishes TORC1
activityinH441cells(assayedbymonitoringthephosphorylation
of S6K-Thr
389; G. Watt and S.C. Land, personal communication)
this result, in contrast with the data presented by Hong et al. [47],
indicates that TORC1 is not important to the control of SGK1.
This ﬁnding does, however, accord well with results recently
presented by Garc´ ıa-Mart´ ınez and Alessi [23], who showed
that the apparent phosphorylation of SGK1-Ser
422 by TORC1 is
almost certainly an artefact.
Signiﬁcance of ﬁndings from the present study
Recently, studies of renal epithelial have indicated that α-ENaC
transcription may be inhibited by a repressor complex [Dot1a
(disruptor of telomeric silencing alternative splice variant a)/Af9
(ALL-1 fused gene from chromosome 9)] that associates with the
α-ENaC gene promoter. This complex appears to be a substrate
for SGK1, which phosphorylates Af9 at Ser
435 thus allowing
Dot1a to dissociate from this gene region and this, in turn,
seems to permit unimpeded transcription [38]. It was therefore
suggested that SGK1 is centrally important to the hormonal
control of α-ENaC transcription [14,38], and this mechanism
could explain the augmentation of the glucocorticoid-induced
α-ENaC transcription that we observe in cells expressing SGK1-
S422D or CD2-P110α. However, it is important to remember that
transient expression of such constitutively active proteins would
almost certainly cause hyperactivation of SGK1/PI3K, and it is
thereforeinterestingthatourresultsalsoshowthatdexamethasone
can activate the α-ENaC gene promoter even when signalling via
SGK1/PI3K has been blocked. Moreover, although irradiation
with UV light increased the activity of endogenous SGK1 via a
pathophysiological mechanism, this manoeuvre did not alter the
activity of the α-ENaC reporter gene construct in unstimulated or
dexamethasone-stimulated cells. Although it is abundantly clear
that glucocorticoids do activate SGK1 in H441 cells (as shown in
the present study and in [24]), the results from the present study,
in contrast with those presented by Zhang et al. [38], suggest
that this kinase can only play a very minor role in the hormonal
control of α-ENaC transcription. It is therefore interesting that
the quantiﬁcation of mRNA levels presented by Zhang et al. (see
Figure6Ein[38])showthatsgk1genedeletionhasonlyamodest
(∼30% inhibition) effect upon α-ENaC mRNA abundance in
the kidneys of mice fed a low-Na
+ diet. This result, in common
with the results from the present study, indicates that substantial
α-ENaC gene transcription must occur independently of SGK1
[38]. Moreover, in the lungs, α-ENaC gene deletion prevents
the absorption of alveolar ﬂuid that normally occurs during the
perinatal period and thus causes death through severe respiratory
distress within ∼48 h of birth [48]. Genetic deletion of the sgk1
gene, on the other hand, does not cause an overt pulmonary
phenotype [49], indicating that at least some α-ENaC gene
transcription must be able to occur independently of this kinase.
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